AkaLumine hydrochloride is a luciferin analogue, with a K_m of 2.06 μM for recombinant Fluc protein.

Km: 2.06 μM (recombinant Fluc protein)^[1].

In both LLC/luc and MDA-MB-231/luc cells treated with AkaLumine hydrochloride, the signal is maximal at lower concentrations (by 2.5 μM), whereas the bioluminescence generated by D-luciferin and CycLuc1 increase as concentrations increase further, not appearing to reach a maximal signal even at 250 μM^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

AkaLumine hydrochloride displays greatly enhanced signals emanating from metastasis in the lung, as demonstrated by 8.1-fold higher with AkaLumine hydrochloride as compared with D-luciferin administration. To evaluate the advantage of AkaLumine hydrochloride over CycLuc1 in detecting targets in deep tissue, bioluminescence images are compared between AkaLumine hydrochloride- and CycLuc1-treated mice 15 min after intravenous injection of LLC/luc cells at the dose of 5 mM, which is the maximum concentration of CycLuc1 due to its low water solubility. AkaLumine hydrochloride exhibits 3.3-fold increase in detection sensitivity of disseminated cancer cells in the lung compared with CycLuc1. The advantage of AkaLumine hydrochloride is further confirmed by imaging the same mice bearing lung metastasis after intraperitoneal injection of 5 mM substrates in order of CycLuc1 and AkaLumine hydrochloride, and in the inverse order at an 8-h interval. AkaLumine hydrochloride displays about fourfold increase in signals from lung metastasis compared with CycLuc1^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

338.85

C₁₆H₁₉ClN₂O₂S

2558205-28-8

Room temperature in continental US; may vary elsewhere.

-20deg;C, stored under nitrogen

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

In Vitro:;

DMSO : 80 mg/mL (236.09 mM; Need ultrasonic)

H₂O : 50 mg/mL (147.56 mM; Need ultrasonic)

*

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂：;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

  Solubility: ≥ 4 mg/mL (11.80 mM); Clear solution

  此方案可获得 ≥ 4 mg/mL (11.80 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 40.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

• 2.

  请依序添加每种溶剂：;10% DMSO ;; 90% (20% SBE-β-CD in saline)

  Solubility: ≥ 4 mg/mL (11.80 mM); Clear solution

  此方案可获得 ≥ 4 mg/mL (11.80 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 40.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明

• [1]. Kuchimaru T, et al. A luciferin analogue generating near-infrared bioluminescence achieves highly sensitive deep-tissue imaging. Nat Commun. 2016 Jun 14;7:11856.